首页> 外国专利> ANTI-MORPHINE ANTIBODY, METHOD FOR MEASURING MORPHINE USING THE SAME, AND MORPHINE MEASURING KIT CONTAINING THE SAME

ANTI-MORPHINE ANTIBODY, METHOD FOR MEASURING MORPHINE USING THE SAME, AND MORPHINE MEASURING KIT CONTAINING THE SAME

机译:抗吗啡抗体,使用该抗体测量吗啡的方法以及包含该吗啡的试剂盒

摘要

PROBLEM TO BE SOLVED: To provide a superior anti-morphine antibody capable of recognizing morphine specifically, and having low recognition ability to heroin, codeine, cocaine and ketamine, and to thereby facilitate measurement of morphine in a sample.SOLUTION: This anti-morphine antibody to be prepared is selected from a group comprising a single-chain antibody (scFv), a Fab fragment, a F(ab')fragment, a Fv fragment and a perfect antibody, which comprise anti-morphine antibody molecules capable of recognizing morphine specifically, having low recognition ability to heroin, codeine, cocaine and ketamine, and containing a heavy chain variable region and a light chain variable region, and further the anti-morphine antibody has, in the heavy chain variable region, (a) an amino acid sequence described on the 31th place to the 35th place of SEQ ID NO.1 in the sequence table as CDR-H1, (b) an amino acid sequence described on the 50th place to the 65th place of SEQ ID NO.1 as CDR-H2, and (c) an amino acid sequence described on the 98th place to the 110th place of SEQ ID NO.1 as CDR-H3, and/or also has, in the light chain variable region, (a) an amino acid sequence described on the 160th place to the 174th place of SEQ ID NO.1 in the sequence table as CDR-L1, (b) an amino acid sequence described on the 190th place to the 196th place of SEQ ID NO.1 as CDR-L2, and (c) an amino acid sequence described on the 229th place to the 237th place of SEQ ID NO.1 as CDR-L3.
机译:解决的问题:提供一种高级抗吗啡抗体,该抗体能够特异性识别吗啡,并且对海洛因,可待因,可卡因和氯胺酮的识别能力低,从而有助于测量样品中的吗啡。待制备的抗体选自包含单链抗体(scFv),Fab片段,F(ab')片段,Fv片段和完美抗体的组,所述抗体包含能够识别吗啡的抗吗啡抗体分子具体地,对海洛因,可待因,可卡因和氯胺酮的识别能力低,并且包含重链可变区和轻链可变区,并且抗吗啡抗体在重链可变区中具有(a)氨基在序列表的SEQ ID NO.1的第31位至第35位描述的氨基酸序列为CDR-H1(b)在SEQ ID NO.1的第50位至第65位描述为CDR的氨基酸序列-H2和(c)在SEQ ID NO.1的第98位至第110位描述的氨基酸序列为CDR-H3,和/或在轻链可变区中还具有(a)在第160位的氨基酸序列描述为序列表中SEQ ID NO.1的第174位为CDR-L1,(b)SEQ ID NO.1的第190位至第196位描述为CDR-L2的氨基酸序列,以及(c)在SEQ ID NO.1的第229位至第237位描述的氨基酸序列为CDR-L3。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号